#USA #San Diego #Viking Therapeutics #Obesity Treatment #VK2735

Viking Therapeutics Initiates Clinical Trial for VK2735

Viking Therapeutics, a biopharmaceutical company with a focus on developing innovative treatments for metabolic disorders, has officially launched a clinical trial for VK2735, a novel dual agonist designed to target glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This study is particularly interesting as it aims to determine effective maintenance dosing strategies for patients who have experienced initial weight loss.

The trial, categorized as a Phase 1 randomized, double-blind, placebo-controlled study, will include approximately 180 adult participants diagnosed with obesity (BMI ≥30 kg/m²) but who are otherwise healthy. Initially, all participants will receive weekly subcutaneous injections of VK2735 or a placebo for 19 weeks. After this induction phase, subjects will switch to one of several maintenance dosing regimens. These options include monthly subcutaneous doses, daily oral doses, weekly oral doses, or a continuation of the placebo treatment.

Transformative Dosing Options

Brian Lian, Ph.D., the chief executive officer of Viking Therapeutics, emphasizes the potential of VK2735 as a transformative treatment for obesity. The study's objective is to evaluate the safety and tolerability of various VK2735 dosing regimens while monitoring its pharmacokinetic profile. By analyzing study endpoints, the research team aims to assess changes in body weight from the baseline as well as the efficacy of maintenance strategies from Week 19 to the conclusion of the study at Week 31.

Lian pointed out that identifying effective maintenance regimens is crucial. The flexible dosing options proposed for VK2735 are anticipated to enhance patient adherence to treatment and subsequently optimize long-term results, which may include reduced cardiovascular risk and improved overall quality of life.

Continuing Developments and Future Prospects

Alongside this maintenance dosing study, Viking Therapeutics is actively carrying out two Phase 3 clinical trials—VANQUISH-1 and VANQUISH-2. These trials are also designed to evaluate the efficacy and safety of VK2735 administered subcutaneously once weekly over a 78-week period. VANQUISH-1 aims to enroll approximately 4,500 adults without type 2 diabetes who are classified as obese or overweight and have at least one weight-related co-morbidity. Meanwhile, the VANQUISH-2 study focuses on 1,100 adults with type 2 diabetes who are similarly classified.

The Science Behind VK2735

The rationale for using GLP-1 and GIP dual agonists like VK2735 lies in their proven ability to combat obesity and improve metabolic health. Activation of GLP-1 receptors contributes to decreased appetite and improved insulin sensitivity, factors crucial for managing conditions like type 2 diabetes and obesity. What sets VK2735 apart is its unique formulation, which integrates the dual agonistic mechanism aimed at maximizing therapeutic outcomes for patients.

Semaglutide, a well-known GLP-1 receptor agonist approved by the FDA, exemplifies anticipated results, as it has established a foothold in obesity treatment through effective appetite suppression and weight reduction. VK2735 aspires to build on this success while potentially offering an oral formulation to broaden its prescribing options.

Viking Therapeutics’ Commitment

Viking Therapeutics continues to demonstrate a strong commitment to advancing its clinical pipeline to improve patient lives. Currently, the company is also working on VK2809, another innovative therapy aimed at treating lipid and metabolic disorders, alongside its ongoing efforts in developing dual amylin and calcitonin receptor agonists for obesity treatment. Additionally, the investigational compound VK0214 is being explored for treating X-linked adrenoleukodystrophy (X-ALD), showcasing the breadth of Viking's innovative research and development in metabolic diseases.

As Viking Therapeutics proceeds with its extensive research agenda, results from the ongoing maintenance dosing study for VK2735 are anticipated to shed light on future treatment possibilities for obesity, contributing another critical tool in the ongoing battle against this pervasive health issue. The company is expected to report findings from this study in 2026, which will add invaluable insights into the management of obesity and its associated risks.